These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30690720)

  • 21. Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model.
    Steven Ernest C; Nyberg J; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):639-54. PubMed ID: 25308776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome-dependent sampling with interval-censored failure time data.
    Zhou Q; Cai J; Zhou H
    Biometrics; 2018 Mar; 74(1):58-67. PubMed ID: 28771664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical inference for serial dilution assay data.
    Lee ML; Whitmore GA
    Biometrics; 1999 Dec; 55(4):1215-20. PubMed ID: 11315070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of statistical experimental designs to improve statistical inference in weed management.
    Kim SB; Kim DS; Magana-Ramirez C
    PLoS One; 2021; 16(9):e0257472. PubMed ID: 34525126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simulation study comparing different experimental designs for estimating uptake and elimination rates.
    Bell BR; Bailer AJ; Wright SE
    Environ Toxicol Chem; 2006 Jan; 25(1):248-52. PubMed ID: 16494249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How often should we expect to be wrong? Statistical power, P values, and the expected prevalence of false discoveries.
    Marino MJ
    Biochem Pharmacol; 2018 May; 151():226-233. PubMed ID: 29248599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MUlti-Dimensional Spline-Based Estimator (MUSE) for motion estimation: algorithm development and initial results.
    Viola F; Coe RL; Owen K; Guenther DA; Walker WF
    Ann Biomed Eng; 2008 Dec; 36(12):1942-60. PubMed ID: 18807190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multilevel Meta-Analysis of Individual Participant Data of Single-Case Experimental Designs: One-Stage versus Two-Stage Methods.
    Declercq L; Jamshidi L; Fernández Castilla B; Moeyaert M; Beretvas SN; Ferron JM; Van den Noortgate W
    Multivariate Behav Res; 2022; 57(2-3):298-317. PubMed ID: 32996335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selecting the best design for nonstandard toxicology experiments.
    Webb JM; Smucker BJ; Bailer AJ
    Environ Toxicol Chem; 2014 Oct; 33(10):2399-406. PubMed ID: 24943385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
    Foffi G; Pastore A; Piazza F; Temussi PA
    Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimum design of experiments for enzyme inhibition kinetic models.
    Bogacka B; Patan M; Johnson PJ; Youdim K; Atkinson AC
    J Biopharm Stat; 2011 May; 21(3):555-72. PubMed ID: 21442525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.
    Choodari-Oskooei B; Parmar MK; Royston P; Bowden J
    Trials; 2013 Jan; 14():23. PubMed ID: 23343147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An examination of effect estimation in factorial and standardly-tailored designs.
    Allore HG; Murphy TE
    Clin Trials; 2008; 5(2):121-30. PubMed ID: 18375650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental design and estimation of parameters in complex radioligand binding systems.
    Staschen CM; Homer LD
    J Pharmacokinet Biopharm; 1996 Dec; 24(6):589-609. PubMed ID: 9300352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximum-likelihood estimation for indicator dilution analysis.
    Kuenen MP; Herold IH; Korsten HH; de la Rosette JJ; Wijkstra H; Mischi M
    IEEE Trans Biomed Eng; 2014 Mar; 61(3):821-31. PubMed ID: 24239967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal-design domain-adaptation for exposure prediction in two-stage epidemiological studies.
    Sarafian R; Kloog I; Rosenblatt JD
    J Expo Sci Environ Epidemiol; 2023 Nov; 33(6):963-970. PubMed ID: 35459930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model-free numerical deconvolution of recirculating indicator concentration curves.
    Clough AV; Cui D; Linehan JH; Krenz GS; Dawson CA; Maron MB
    J Appl Physiol (1985); 1993 Mar; 74(3):1444-53. PubMed ID: 8482689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.